Tag Archives: Obamacare

Physicians Won’t Change Their Practices Without Worthwhile Incentives

By Mark Wagar. (This blog first appeared on Managed Healthcare Executive.) There is more collaboration than ever between payers and providers in the drive to provide high-quality, cost-effective care to diverse populations across the United States. According to a January 2014 Centers for Medicare and Medicaid Services (CMS) report, the accountable care organization (ACO) model is […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , , , , | Leave a comment

Things Looking Up for Obamacare, But New HHS Chief Faces Tough 2015

This blog previously ran on Managed Healthcare Executive. The Obama administration received a substantial amount of good news last month. Not only did 8 million individuals enroll in qualified health plans, millions more joined Medicaid or obtained coverage through private markets. Additionally, health reform will cost $100 billion less than anticipated, according to the Congressional […]
Posted in healthcare, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Posted in Biotech, Guest Blog, healthcare, leadership, Legal, Market Access, Strategy | Also tagged , , , , , , | 2 Comments

Medicare Data Raises Questions About Drug Costs

The recently released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays, but opens the door to scrutiny of Medicare reimbursement for medicines delivered in physician offices, writes Jill Wechsler. The Centers for Medicare and Medicaid Services (CMS) has released data on payments to some 880,000 healthcare providers who collectively […]
Posted in FDA, Regulatory | Also tagged , , , | 2 Comments

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 1 Comment
  • Categories

  • Meta